Please login to the form below

Not currently logged in


This page shows the latest IOmet news and features for those working in and with pharma, biotech and healthcare.

Merck & Co buys another immuno-oncology target

Merck & Co buys another immuno-oncology target

Other deals have included the acquisitions of IOmet last year, cCAM Biotherapeutics in 2015 and OncoEthix a year earlier.

Latest news

  • Merck & Co buys IOmet to boost immuno-oncology tech Merck & Co buys IOmet to boost immuno-oncology tech

    Merck &Co buys IOmet to boost immuno-oncology tech. Reports suggest it paid up to £280m for the Scottish biopharma company. ... IOmet will become a wholly owned subsidiary of Merck after the transaction goes through, according to Merck.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...